LAS VEGAS, Aug. 4, 2014 /PRNewswire via COMTEX/ –– BioAdaptives, Inc. (OTCBB:BDPT) announced results of the clinical trial completed on “PRIMICELL(TM)” which resulted in the research and development of 8 new products.
PRIMICELL(TM) is a trademarked name of the first product BioAdaptives, Inc. will bring to market through private labeling and exclusive licensing agreements worldwide. BioAdaptives, Inc. Chairman and CEO, Barry Epling said, “During the human clinical trial, glucose, routine hematology and chemistry parameters, kidney function and liver function were measured. The results demonstrated that no negative changes were found, supporting the conclusion that PRIMICELL(TM) blend is safe.”
Epling added, “In addition to proving the product safe, the participants who took PRIMICELL(TM) on average showed a 268% increase of circulating, primitive stem cells. These results, coupled with additional scientific studies on the product, have led us to begin broader research on PRIMICELL and on 8 new, unique products in the fields of anti-aging, sports recovery, weight-loss, assisting in focus, lessening atherosclerosis, as well as regenerative help for felines and canines. These products are each in a different stage of development. Two are near completion in research and development and will be brought to market soon.”
With additional studies and trials continuing both in the United States and Overseas, Epling stated, “We are very excited at the findings to date and each new study reveals new and valuable benefits, opening doors for a wider array of products that can meaningfully better the lives of both humans and animals. It is very exciting to be a part of this.”
About BioAdaptives, Inc.
BioAdaptives, Inc. is a fully-reporting, public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for human and animal consumption. The company’s focus, in conjunction with Ferris Holding, Inc., is to source high quality, unique, raw material worldwide and develop science-based products to improve health and wellness in both humans and animals. BioAdaptives, Inc., has developed a proprietary method that is a non-intrusive bioelectromagnetic device for improving individual ingredients, food, beverages, and wellness.
SAFE HARBOR ACT
Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc. and its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc.’s filings with the Securities and Exchange Commission.
Investor Relations: (1) 888-280-0789